Skip to content

Study · Randomized controlled trial · n = 44 · 2012

4 results

Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.

Tseng YY, Su CH, Lui TN, Yeh YS, Yeh SH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA19 Jul 2011Cited by 28 (Europe PMC)

PMID21769661 (opens in a new tab)PMCIDPMC3332357 (opens in a new tab)DOI10.1007/s00198-011-1730-y (opens in a new tab)PepBankPUB-21769661
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with adjacent vertebral compression fractures after vertebroplasty, teriparatide alone was reported to give a lower incidence of new vertebral fractures than repeated vertebroplasty with an antiresorptive (odds ratio 0.21, 95% CI 0.02-2.10).

    In plain wordsNew vertebral fractures were reported less often with teriparatide than with repeated vertebroplasty plus an antiresorptive, though the confidence interval was wide (0.02-2.10).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew vertebral compression fractures
    Study

    n = 44

    Comparator
    Additional vertebroplasty with an antiresorptive agent
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    0.21 ratio
    teriparatide versus group B
    Fracture reduction
    78.57%
    teriparatide

    Source sentences

    Summary
    Patients treated with teriparatide had a significantly lower incidence of new-onset VCFs (odds ratio = 0.21; 95% confidence interval, 0.02-2.10). Teriparatide-mediated VCF reduction was 78.57%, which was markedly better than that of group B.
    1 context sentence
    Summary · context
    Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with adjacent vertebral fractures, lumbar spine BMD increased more with teriparatide than with repeated vertebroplasty and antiresorptive treatment.

    In plain wordsSpine bone density increased more with teriparatide than with repeated vertebroplasty and antiresorptive treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 44

    Comparator
    Additional vertebroplasty with an antiresorptive agent
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    BMD increase
    21.7%
    teriparatide
    BMD increase
    6.87%
    group B

    Source sentences

    Summary
    The increase in lumbar spine BMD was marked in the teriparatide group (21.70% vs. 6.87%) after an 18-month treatment.
    1 context sentence
    Summary · context
    Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with adjacent vertebral fractures, pain scores decreased after teriparatide compared with baseline.

    In plain wordsPain scores decreased after teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVisual analog pain score
    Study

    n = 22

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The teriparatide group had a significant decrease in the visual analog scale and an increase in the Japanese Orthopedic Association low back pain score after 6 months of treatment (p < 0.05).
    1 context sentence
    Summary · context
    Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with adjacent vertebral fractures, teriparatide increased the Japanese Orthopedic Association score compared with baseline.

    In plain wordsThe back pain assessment score increased after teriparatide compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseJapanese Orthopedic Association low back pain score
    Study

    n = 22

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The teriparatide group had a significant decrease in the visual analog scale and an increase in the Japanese Orthopedic Association low back pain score after 6 months of treatment (p < 0.05).
    1 context sentence
    Summary · context
    Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.